Wikipedia -WSS

Wikipedia

author：explore 2025-08-28 08:47:05 - browse：8288

A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT — Jonathan Wiggs /Globe Staff

Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Gritstone Bio's cancer vaccine test, and more on Novartis' deal

hotspot

WSS

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

A protest over insulin prices is seen as a fight for life

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Unique patient identifier: Experts argue the benefits, pitfalls

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Walensky prepares to leave CDC — and Congress — behind

Trump team launching legal defense fund to help pay legal bills

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

BioMarin wins approval for gene therapy to treat hemophilia A

'Weather

leisure time

HCA says smaller share of spending going to labor

Campaign finance charge dropped from case against Sam Bankman

Readout Newsletter: Amgen, Regeneron, BGI Group and more

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Problems with a popular proposal to regulate AI in health care

hotspot

focus

explore

hotspot